• Protocols

• NCI10276

  OPEN TO ACCRUAL

  Ph1/2 Avelumab +/- M3814 w/ Hypofractionated XRT in Adv/Met Solid Tumors/HPB
  
  

• UW24147

  OPEN TO ACCRUAL

  Ph 2 Study of Casdozokitug w/Toripalimab + Bevacizumab in Participants With Hepatocellular Carcinoma